Sulforaphane Ameliorates Non-Alcoholic Fatty Liver Disease in Mice by Promoting FGF21/FGFR1 Signaling Pathway

Scientists investigated whether fibroblast growth factor 21 (FGF21) was involved in the therapeutic effect of sulforaphane against non-alcoholic fatty liver disease.